DNTH Insider Trading Activity and SEC Form 4 Filings
DNTH insider trading summary
Over the past 12 months, insiders at Dianthus Therapeutics, Inc. (DNTH) reported 62 sales worth $65.9M by 8 insiders and no open-market purchases on SEC Form 4. Net insider selling was $65.9M.
Latest DNTH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 17, 2026 | Edward Carr | Chief Accounting Officer | Sell | $114K (1,100 @ $103.20) |
| Sep 17, 2026 | Edward Carr | Chief Accounting Officer | Sell | $73K (700 @ $104.39) |
| Sep 17, 2026 | Edward Carr | Chief Accounting Officer | Sell | $796K (7,928 @ $100.43) |
| Sep 17, 2026 | Edward Carr | Chief Accounting Officer | Sell | $686K (6,771 @ $101.37) |
| Sep 17, 2026 | Edward Carr | Chief Accounting Officer | Sell | $358K (3,501 @ $102.39) |
| Sep 1, 2026 | Simrat Randhawa | EVP, Head of R&D | Sell | $1.4M (13,309 @ $106.74) |
| Sep 1, 2026 | Simrat Randhawa | EVP, Head of R&D | Sell | $273K (2,600 @ $105.19) |
| Sep 1, 2026 | Simrat Randhawa | EVP, Head of R&D | Sell | $767K (7,215 @ $106.25) |
| Aug 19, 2026 | Simon Read | Insider | Sell | $327K (2,778 @ $117.55) |
| Aug 10, 2026 | Anne McGeorge | Insider | Sell | $156K (1,450 @ $107.58) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.